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The recent availability of a sensitive chromogenic method approach for determina-
tion of FXIa activity has been explored for designing sensitive methods for FXIIa and 
kallikrein, both using FXa formation as the read-out. For both enzymes the assay range 
1–10 nmol/L provides a resolution of about 0.8 absorbance units with a total assay time 
of about 20 min. For studies on activation kinetics, subsampling and extensive dilution 
can be performed in MES–bovine serum albumin (BSA) buffer pH 5.7 for quenching of 
enzyme activity and with ensuing determination of FXa generation in a chromogenic 
FXIa method. Optionally, suitable inhibitors such as aprotinin and/or corn trypsin inhibitor 
may be included. The stability of FXIa, FXIIa, and kallikrein in MES–BSA buffer was 
shown to be at least 5 h on ice. In conclusion, the use of a sensitive chromogenic FXIa 
method either per  se or in combination with MES–BSA buffer pH 5.7 are new and 
potentially valuable tools for the study of contact factor enzymes and their inhibitors. So 
far, dose–response studies of FXIIa and kallikrein have been limited to purified systems, 
and hence more data are required to learn whether these new methods might or might 
not be applicable to the determination of FXIIa and kallikrein activities in plasma.
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iNtrODUctiON
The contact activation pathway, involving factor XII (FXII), prekallikrein (PK), high molecular 
weight kininogen (HK), and factor XI (FXI) displays complex interactions and is involved in both 
coagulation and inflammation [for reviews, see Ref. (1, 2)]. Much research has been devoted to this 
area during the last 20 years, partly due to the findings that FXI can be activated on the platelet 
surface by thrombin (3–8) and also due to the more recent interest in anti-FXI antibodies and FXI 
antisense nucleotides as antithrombotic agents (9–13).
In vivo as well as for in vitro studies on plasma, contact activation is surface-bound, i.e., contact 
factors assemble on a negatively charged surface with the initial step being binding and autoactiva-
tion of FXII. PK and FXI bind to the surface through HK. In vitro, this is utilized in any APTT-based 
method, and the negatively charged surface is provided as a constituent in the APTT reagent, typi-
cally as some variant of silica or as ellagic acid.
Studies performed more than 40 years ago demonstrated that surface-bound FXII and FXI are 
much more effectively activated than in solution and also that HK is a cofactor to such activation, 
however not a mandatory requirement (14–16).
More recently, sensitive chromogenic methods for FXIa have been developed and made avail-
able as commercial kits (17, 18). These products were originally developed for detection of trace 
amounts of FXIa as contaminant in pharmaceutical products such as intravenous immunoglobulins. 
However, the chromogenic FXIa method has also been applied for investigation of FXI activation 
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during contact activation on analysis of a one-stage method 
for potency assignment of the extended half-life rFIX product 
N9-GP (19). Here, subsampling and dilution into a low pH buffer 
was used to quench further activation. This combined approach 
has now been explored for designing sensitive methods for FXIIa 
and kallikrein. Part of this work was presented at the ISTH/SSC 
meeting in May 2016 (20).
MAteriALs AND MetHODs
Chromogenic kit Rox Factor XIa (Rossix AB, Molndal, Sweden) 
was used for photometric determination of FXIa activity. The 
kit comprises two lyophilized reagents, one containing human 
factor IX, human factor VIII, and calcium chloride and the 
other containing human factor X, bovine thrombin, phospho-
lipids, and calcium chloride. The chromogenic FXa substrate 
Carboxybenzyl-D-Arg-Gly-Arg-pNA is included in the kit as 
a liquid solution. The limit of quantitation in the assay is about 
0.02  mIU/mL, calibrated vs. the WHO first Int Std FXIa (ref 
13/100). This corresponds roughly to 0.01 pmol/L of FXIa.
Bovine serum albumin (BSA) was approved for use as a bulk-
ing agent of coagulation proteins (Rossix AB).
The coagulation proteins human FXI, human FXIa, human 
FXII, human αFXIIa, human PK, human plasma kallikrein (kal-
likrein), and corn trypsin inhibitor (CTI) were all from Enzyme 
Research Laboratories (South Bend, IN, USA).
Frozen human normal pooled plasma (NPL) was from 
Precision Biologics (Dartmouth, Canada).
Activated partial thromboplastin reagent APTT SP was from 
Instrumentation Laboratory, Bedford, MA, USA.
Bovine lung aprotinin was from Sigma-Aldrich, St Louis, MI, 
USA.
Tris(hydroxymethyl)aminomethane (Tris), Tris hydrochlo-
ride, 2-(N-morpholino)ethanesulfonic acid (MES), and sodium 
chloride were from Sigma-Aldrich. All chemicals were of reagent 
grade.
MES–BSA buffer was prepared to contain 0.05 mol/L MES pH 
5.7, 0.05 M NaCl, 0.2% BSA.
Also, 0.1 mol/L Tris buffer pH 8.3 (25°C) was used for neu-
tralization in assays with samples in MES buffer.
Dilution of coagulation proteins was made in 0.05 mol/L Tris 
buffer pH 7.5 (25°C), 0.1 mol/L NaCl, 1% BSA, denoted working 
buffer solution (WBS).
Determination of FXia Activity
FXIa activity was determined with the Rox Factor XIa kit method. 
The activity is expressed in milli-international units per milliliter.
Determination of FXiia Activity through 
Generation of FXia
At different doses, 25 μL FXIIa was mixed in microplate wells with 
50 μL FXI and 25 μL WBS, whereafter 25 μL APTT SP was added 
to provide a contact activation surface. Final concentrations were 
0, 1–10 nmol/L of FXIIa, and 40 nmol/L of FXI.
The activation of FXI was allowed to proceed for 6 min at 37°C 
followed by addition of 50 μL CTI (final concentration 0.35 μM) 
for inactivation of FXIIa. After a further incubation for 2 min at 
20–25°C to ensure complete inactivation of FXIIa, simultaneous 
consecutive dilutions of all incubation mixtures were made in 
MES–BSA buffer in microplate wells to reach a 250-fold dilution.
Then, generated FXIa activity was determined with the Rox 
Factor XIa kit method and with supplementation of 0.1  mol/L 
Tris buffer pH 8.3 for neutralization.
Determination of Kallikrein Activity 
through Generation of FXia via FXii 
Activation
At different doses, 25 μL kallikrein was mixed in microplate wells 
with 50 μL FXI, 8 μL FXII, and 25 μL WBS whereafter 25 μL 
APTT SP was added to provide a contact activation surface. Final 
concentrations were 0, 1–10 nmol/L of kallikrein, 40 nmol/L of 
FXI, and 93 nmol/L of FXII.
The activation of FXII and FXI was allowed to proceed for 
6  min at 37°C followed by addition of 50 μL CTI (final con-
centration 4 μg/mL) for inactivation of FXIIa. After a further 
incubation for 2 min at 20–25°C to ensure complete inactivation 
of FXIIa, simultaneous consecutive dilutions of all incubation 
mixtures were made in MES–BSA buffer in microplate wells to 
reach 50- and 200-fold dilutions.
Then, generated FXIa activity was determined with the Rox 
Factor XIa kit method and with supplementation of 0.1  mol/L 
Tris buffer pH 8.3 for neutralization.
stability tests in Mes–BsA Buffer
The above biological activity methods for FXIa, FXIIa, and 
kallikrein were utilized to study the stability of these enzymes 
in MES–BSA buffer. WBS was first diluted fourfold in water to 
decrease its buffering capacity and then used for suitable predilu-
tion of each enzyme. These were subsequently 21-fold diluted in 
ice cold MES–BSA buffer and kept on ice. Also, 50 μL aliquots 
were withdrawn from each enzyme solutions at time points 0, 
1, 2, 3, 4, and 5 h and immediately frozen at −70°C and kept at 
−70°C until analysis. The biological activities of FXIa, FXIIa, and 
kallikrein were then determined as described above.
Determination of stability of FXia Added 
to Plasma or Generated in Plasma via 
contact Activation
Contact-Activated FXI
Three hundred and thirty microliter NPL was contact activated 
with 165 μL APTT SP for 5 min, followed by addition of 20 μL of 
CTI (final concentration 4 μg/mL) and 20 μL of aprotinin (final 
concentration 350  KIU/mL) to inhibit FXIIa and kallikrein, 
respectively. The concentration used of aprotinin inhibited >98% 
of kallikrein activity and about 70% of FXIa activity.
A first subsampling was then immediately made of 10 μL into 
3  mL MES–BSA buffer (301-fold dilution) followed by further 
subsamplings after 30 s and up to 20 min.
FXIa Spiked into Plasma
Twenty microliter FXIa was added to 480  μL human normal 
plasma and subsampling was made of 10 μL into 3 mL MES–BSA 
FiGUre 2 | stability of human FXia in normal plasma after formation via 
contact activation with APtt sP ( ) or after spiking into plasma ( ).
FiGUre 1 | Dose–response curves for FXia ( ), FXiia ( ), and 
kallikrein ( ) using APtt sP as contact surface provider. The 
dose–response curve for kallikrein in the absebce of APTT SP ( ) is also 
shown. The higher blank value for FXIIa and kallikrein as compared to FXIa is 
due to presence of FXIa in the FXI zymogen preparation.
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buffer after 30 s followed by further subsamplings up to 20 min. 
The zero time sample was obtained by adding 10 μL of a 25-fold 
lower FXIa concentration directly to 3 mL MES–BSA buffer.
The FXIa activity was then determined as described above.
resULts
Dose–response curves for FXia, FXiia, 
and Kallikrein
Figure 1 shows dose–response curves for FXIa (1–10 mIU/mL), 
FXIIa (1–10  nmol/L), and kallikrein (1–10  nmol/L) using FXa 
formation as the read-out with the Rox Factor XIa kit and hence 
expressing biological functional activities of these enzymes.
For all enzymes, the resolution was at least 0.8 absorbance 
units in the tested ranges. The blank activity of about 0.2 absorb-
ance units noticed for the FXIIa and kallikrein curves is due to 
contaminating FXIa in the used FXI zymogen preparation.
stability of FXia, FXiia, and Kallikrein in 
Mes–BsA Buffer
The stability of FXIa, FXIIa, and kallikrein was determined after 
storage for up to 5 h in ice cold MES–BSA buffer pH 5.7 using 
the above methods. For all enzymes, the recovery of activity was 
between 95 and 102% of the initial activity during the 5-h storage 
time. Similar results were also obtained from determination of 
enzyme activities with direct hydrolysis of suitable chromogenic 
substrates (data not shown).
stability of FXia Added to Plasma or 
Generated in Plasma via contact 
Activation
Figure 2 shows that about 85% of the FXIa activity was lost 6 min 
after spiking of FXIa to plasma, whereas about 96% of the FXIa 
activity remained after 6  min when generated during contact 
activation. The activity then fell gradually but was still above 80% 
after 20 min storage.
DiscUssiON
The high sensitivity of the chromogenic FXIa method (0.02 mIU/
mL or about 0.01 pmol/L) allows extensive sample dilutions to 
minimize or eliminate interferences from sample matrices. 
This has been utilized in the present study for designing bio-
logical activity methods also for FXIIa and kallikrein as shown in 
Figure 1. Such methods reflect the functional, biological activ-
ity in contrast to direct amidolytic methods in which suitable 
chromogenic substrates are directly cleaved by FXIa, FXIIa, and 
kallikrein. Such methods may not always reflect the biological 
activity as is illustrated, e.g., by γ-thrombin, which cleaves low 
molecular chromogenic substrates but splits its natural substrate 
fibrinogen very poorly (21). Furthermore, enzymes in complex 
with α2-macroglobulin usually cleave chromogenic substrates but 
not natural protein substrates (22–25).
The FXIIa and kallikrein methods should be regarded as “prin-
ciple approaches,” demonstrating their feasibility but not claimed 
to be optimized. Thus, doubling the FXII zymogen concentration 
in the kallikrein method gave a significant increased rate of FXII 
activation by kallikrein, and hence an increase in FXIa generation 
resulting in about 50% higher FXa formation (data not shown). 
The utilized concentration range, 1–10  nmol/L for FXIIa and 
kallikrein, corresponds to about 0.25–2.5% and 0.18–1.8% of the 
plasma zymogen concentrations of FXII and PK, respectively. The 
methods may tentatively be further amplified by including also 
the prothrombinase complex in the final step and thus use throm-
bin formation rather than generation of FXa as the read-out.
Common for all three methods is the use of a contact activa-
tor (APTT SP) as a surface provider and trigger of activation. 
Importantly, HK does not have to be present in agreement with 
earlier findings (16).
It is also worth mentioning that the used concentrations of 
CTI and aprotinin only cause ≤5% inhibition of the FXa genera-
tion (data not shown).
The demonstrated stability of FXIa, FXIIa, and kallikrein in 
MES–BSA buffer pH 5.7 may be conveniently utilized in, e.g., 
studies on activation kinetics where subsampling and extensive 
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dilutions in MES–BSA buffer followed by chromogenic FXIa deter-
mination provides a sensitive and robust tool for such studies (19).
This combined concept was also utilized in the present study 
to demonstrate a pronounced difference in FXIa stability when 
formed during contact activation in plasma as compared to addi-
tion of FXIa in plasma (Figure 2). The higher stability of FXIa in 
the former case is due to protection of FXIa by HK in the contact 
factor complex (26). The slow inhibition of generated FXIa, with 
about 20% inhibition after 20 min is caused by several protease 
inhibitors, primarily C1-esterase inhibitor, α2-antiplasmin, and 
α1-antitrypsin (27).
A further illustration on the advantage with the high sensitivity 
of the FXIa method is the use of aprotinin for efficient inhibition 
of kallikrein. Even though the used concentration, 350 KIU/mL, 
of aprotinin caused about 70% inhibition of FXIa, sufficient FXa 
generation in the chromogenic FXIa method was easily obtained.
In conclusion, the use of a sensitive chromogenic FXIa method 
either per se or in combination with MES–BSA buffer pH 5.7 may 
be valuable tools for study of contact factor enzymes and their 
inhibitors.
The system may tentatively be further amplified by using 
thrombin formation rather than generation of FXa as the 
end-point.
sUMMArY
The recent availability of a sensitive chromogenic method 
approach for the determination of FXIa activity has been 
explored for designing sensitive methods for FXIIa and kal-
likrein, both using FXa formation as the read-out. For both 
enzymes the assay range 1–10  nmol/L provides a resolution 
of about 0.8 absorbance units with a total assay time of about 
20 min.
For studies on activation kinetics, subsampling and exten-
sive dilution can be performed in MES–BSA buffer pH 5.7 for 
quenching of enzyme activity, optionally including aprotinin 
and/or CTI, and with ensuing determination of FXa generation 
in the chromogenic FXIa method.
The stability of FXIa, FXIIa, and kallikrein in MES–BSA buffer 
was shown to be at least 5 h on ice.
In conclusion, the use of a sensitive chromogenic FXIa method 
either per se or in combination with MES–BSA buffer pH 5.7 are 
new and potentially valuable tools for study of contact factor 
enzymes and their inhibitors. It should be noted that these assays 
have not been evaluated for the determination of FXIIa and kal-
likrein in patients’ plasma.
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